
CLAIMS

What is claimed is:


1. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein an amount of from about 0.01 mg to about 5 mg per day of the compound is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


2. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein (i) a therapeutically effective amount of the compound in combination with (ii) an anti-CD20 antibody is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


3. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein (i) a therapeutically effective amount of the compound in combination with (ii) an histone deacetylase (HDAC) inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


4. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein (i) a therapeutically effective amount of the compound in combination with (ii) a proteasome inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


5. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein (i) a therapeutically effective amount of the compound in combination with (ii) an anti-CD38 antibody is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


6. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein (i) a therapeutically effective amount of the compound in combination with (ii) an anti-SLAMF7 antibody is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


7. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein (i) a therapeutically effective amount of the compound in combination with (ii) a nuclear export inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


8. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein (i) a therapeutically effective amount of the compound in combination with (ii) a BCL-2 inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

9. Use of a compound in the manufacture of a medicament for treating or managing cancer, wherein (i) a therapeutically effective amount of a compound in combination with (ii) an immune checkpoint inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

10. The use of any one of claims 1 to 9, wherein the cancer is non-Hodgkin lymphoma (NHL).

11. The use of claim 10, wherein the NHL is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), or primary central nervous system lymphoma (PCNSL).

12. The use of claim 10, wherein the NHL is relapsed or refractory NHL.

13. The use of claim 12, wherein the NHL is

(a) relapsed or refractory DLBCL;

(b) relapsed or refractory FL;

(c) relapsed or refractory MZL;

(d)relapsed or refractory MCL;

(e) relapsed or refractory PTCL; or

(f) relapsed or refractory PCNSL.

14. The use of claim 12 or 13, wherein the subject has failed at least one prior therapy.

15. The use of any one of claims 1 to 9, wherein the cancer is Hodgkin Lymphoma (HL), particularly wherein the HL is classical Hodgkin Lymphoma (cHL), and/or wherein the HL is relapsed or refractory HL, wherein particularly the HL is relapsed or refractory cHL, and/or wherein the subject has failed at least one prior therapy.

16. The use of any one of claims 1 to 11 and 15, wherein the NHL or HL is newly diagnosed.

17. The use of any one of claims 1 to 16, wherein the compound is to be
(a) administered orally;
(b) administered in an amount of about 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.45 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.75 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg or 1.9 mg per day; or
(c) administered once daily for 21 days followed by 7 days of rest.

18. The use of any one of claims 2 and 10 to 17, wherein the anti-CD20 antibody is obinutuzumab or rituximab.

19. The use of claim 18, wherein
(a) obinutuzumab is to be administered by intravenous infusion, and/or obinutuzumab is to be administered in an amount of about 1000 mg per day, and/or obinutuzumab is to be administered once every 7 days, or once every 4 weeks; or
(b) rituximab is to be administered intravenously, and/or rituximab is to be administered in an amount of about 375 mg/m^2 per day, and/or rituximab is to be administered by subcutaneous infusion, and/or rituximab is to be administered in an amount of about 1400 mg per day, and/or rituximab is to be administered once every 7 days, or once every 4 weeks.

20. The use of any one of claims 3 and 10 to 17, wherein the HDAC inhibitor is citarinostat (ACY-241), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

21. The use of any one of claims 4 and 10 to 17, wherein the proteasome inhibitor is
(a) marizomib (salinosporamide A), or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof;
(b) bortezomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof;
(c) carfilzomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof; or
(d) ixazomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

22. The use of any one of claims 5 and 10 to 17, wherein the anti-CD38 antibody is isatuximab or daratumumab.

23. The use of any one of claims 6 and 10 to 17, wherein the anti-SLAMF7 antibody is elotuzumab.


24. The use of any one of claims 7 and 10 to 17, wherein the nuclear export inhibitor is selinexor, or a geometric isomer or a mixture of geometric isomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

25. The use of any one of claims 8 and 10 to 17, wherein the BCL-2 inhibitor is venetoclax, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

26. The use of any one of claims 9 to 17, wherein the immune checkpoint inhibitor is pembrolizumab, nivolumab, or ipilimumab.

27. The use of any one of claims 1 to 26, wherein dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is also to be administered.

28. The use of any one of claims 1 to 27, wherein the compound is Compound A-S



Compound A-S

or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein particularly the compound is a hydrochloride salt of Compound A-S.